High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

  title={High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.},
  author={Lala M Dunbar and Richard G Wunderink and Michael P. Habib and Leon G. Smith and Alan M Tennenberg and Mohammed M Khashab and Barbara A Wiesinger and Jim X. Xiang and Neringa Zadeikis and James B. Kahn},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  volume={37 6},
Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC) and the ratio of peak plasma concentration (C(max)) to MIC. Increasing the dose of levofloxacin to 750 mg exploits these parameters by increasing peak drug concentrations, allowing for a shorter course of treatment without diminishing therapeutic benefit. This was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 109 extracted citations


Publications referenced by this paper.
Showing 1-10 of 27 references

Correlations of antimicrobial resistance among Streptococcus pneumoniae in the US: 2001–2002 TRUST surveillance [poster C2-1640

  • DF Sahm, C Thornsberry, ME Jones
  • Program and abstracts of the 42nd Interscience…
  • 2002
2 Excerpts

Cumulative clinical trial experience with levofloxacin in community-acquired pneumoniaassociated pneumococcal bacteremia [poster 8.21

  • J Kahn, B Wiesinger, L Drucker
  • Program and abstracts of the 6th International…
  • 2002
1 Excerpt

Similar Papers

Loading similar papers…